Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays
- 1 April 2004
- journal article
- research article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 190 (4), 910-923
- https://doi.org/10.1016/j.ajog.2004.02.005
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Predicting the clinical status of human breast cancer by using gene expression profilesProceedings of the National Academy of Sciences, 2001
- Delineation of prognostic biomarkers in prostate cancerNature, 2001
- Gene-Expression Profiles in Hereditary Breast CancerNew England Journal of Medicine, 2001
- Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2001
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Bayes FactorsJournal of the American Statistical Association, 1995
- The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinomaAmerican Journal of Obstetrics and Gynecology, 1994
- Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.Journal of Clinical Oncology, 1991